

November 25, 2024

The Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai 400 001 Scrip Code: 543427 The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051
Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we attach herewith disclosure letter dated November 21, 2024 received from SBI Mutual Fund, the Shareholder of the Company.

Kindly take the same on record.

Thanking You Yours faithfully

For MedPlus Health Services Limited

Manoj Kumar Srivastava Company Secretary & Compliance Officer FCS 7460

Enclosed: Copy of disclosure



SBI Funds Management Limited

A joint venture between SBI & AMUNDI (CIN - U65990MH1992PLC065289)

FM/CS/2024/359

November 21, 2024

Mr. Manoj Kumar Srivastava Company Secretary and Compliance Officer **Medplus Health Services Limited** H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad, Telangana, 500037.

Sub: Reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/Madam.

We wish to inform you that there has been a change in the shareholding of SBI Mutual Fund under its various schemes, in your company decreasing by 2% from the previous disclosure made by us under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, vide our letter no. FM/CS/2024/321 dated October 07, 2024, wherein the reported holding was 5.0283% of the paid-up share capital of your Company.

SBI Mutual Fund, under its various schemes has sold 10,04,052 shares representing 0.8399% of the paid-up share capital of your Company. The final holding of SBI Mutual Fund, under its various schemes, as at the close of business hours on November 19, 2024, was 2,975,703 shares which is 2.4891% of the paid-up share capital of your Company.

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed the required disclosure, as prescribed in the said regulations.

Thanking you,

Yours faithfully,

For SBI Funds Management Limited

Vacatar.

Chief Compliance Officer & Company Secretary

Encl: As above

c.c. 1. National Stock Exchange of India Limited
Listing Department
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex,

C.c. 1. National Stock Exchange of India Limited
Department of Complex of BSE Limited
Phiroze Jeepeebho

Bandra (East), Mumbai - 400 051. General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeeleebhoy Towers,
Dalal Street,
Mumbai - 400 001

Trustee: SBI Mutual Fund Trustee Company Private Limited (CIN: U65991MH2003PTC138496)

9th Floor, Crescenzo, Plot C-38 & 39, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Tel.: +91 22 61793000 | Fax: +91 22 67425687-91 | Website: www.sbimf.com



SBI Funds Management Limited

A joint venture between SBI & AMUNDI (CIN - U65990MH1992PLC065289)

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Tormat for disclosures under Regulation 23(2)	of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011		
Name of the Target Company (TC)	MEDPLUS HEALTH SERVICES LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	SBI Mutual Fund under its various schemes		
Whether the acquirer belongs to Promoter/Promoter group	N.A.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Ltd / National Stock Exchange of India Ltd		
5. Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC(**)
Before the acquisition/disposal under consideration, holding			
of:			
a) Shares carrying voting rights	39,79,755	3.3290%	N.A.
b) Share in the nature of encumbrance (pledge/ lien/ non- disposal undertaking/ others)	N.A.	N.A.	N.A.
c) Voting rights (VR) otherwise than by shares	N.A.	N.A.	N.A.
 d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category) 	N.A.	N.A.	N.A.
Total (a+b+c+d)	39,79,755	3.3290%	N.A.
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	10,04,052	0.8399%	N.A.
b) VRs acquired /sold otherwise than by shares	N.A.	N.A.	N.A.
 c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold 	N.A.	N.A.	N.A.
d) Shares encumbered/ invoked/ released by the acquirer Total (a+b+c+d)	Ν.Λ.	N.A.	N.A.
After the acquisition/sale, holding of:	10,04,052	0.8399%	N.A.
a) Shares carrying voting rights	29,75,703	2.4891%	N.A.
b) Shares encumbered with the acquirer	N.A.	N.A.	N.A.
c) VRs otherwise than by shares	N.A.	N.A.	N.A.
 d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition. 	N.A.	N.A.	N.A.
Total (a+b+c+d)	29,75,703	2.4891%	N.A.
 Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc). 	Market Sale		
 Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable 	Sold 1,004,052 shares on 19-November-2024		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 23,90,94,312 consisting of 11,95,47,156 equity shares having a face value of Rs. 2/- each.		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 23,90,94,312 consisting of 11,95,47,156 equity shares having a face value of Rs. 2/- each.		
 Total diluted share/voting capital of the TC after the said acquisition/sale. 	N.A.		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity

the west

Raviprakash Sharma

Chief Dealer

Signature of the acquirer/ seller/ Authorised Signatory

Place: Mumbai

Date: 21-November-2024

Aparna Nirgude Chief Risk Officer